ACE-MAB

ACE-MAB is an investigational antiviral **bi-specific fusion protein** being developed by Sorrento and Mabpharm for the potential treatment of **COVID-19**. Public disclosures describe it as a proprietary molecule that binds the **spike protein** of coronaviruses including SARS-CoV-2 and SARS-CoV, with the intended mechanism of blocking viral engagement of **ACE2**-expressing respiratory epithelial cells and thereby interrupting viral entry and the viral life cycle. The candidate appears to have remained at a **preclinical or manufacturing-enabling stage**, with disclosures indicating cGMP cell-line development rather than established clinical-stage advancement.

Other names

ACE-MAB fusion proteinAcemab